CClinicalTrials.gg
CompletedNCT07490574TIDEUpdated Mar 31, 2026

Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion

An interventional study of Underwater ESD (UESD) and Conventional Gas-Assisted ESD (GESD) in Colorectal Neoplasia, Colorectal Superficial Neoplasia and Colorectal Precancerous Lesions, sponsored by University of Roma La Sapienza. Completed at 1 site in Italy. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by University of Roma La Sapienza · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2024, registered Mar 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Colorectal endoscopic submucosal dissection (ESD) enables en bloc resection of large superficial colorectal neoplasia but remains technically demanding and may be limited by suboptimal visualization, intraprocedural bleeding, smoke accumulation, and prolonged procedural time. Underwater ESD (UESD), performed under saline immersion rather than gas insufflation, has been proposed as a strategy to improve the operative field and facilitate submucosal dissection.

This prospective, multicenter, open-label, randomized controlled trial was designed to compare UESD with conventional gas-assisted ESD (GESD) for colorectal neoplasia referred for ESD across Italian tertiary centers. The primary objective was to assess non-inferiority of UESD versus GESD in terms of en bloc resection. Secondary objectives included comparison of histological resection quality, procedural efficiency, intraprocedural events, procedural field visualization, and post-procedural adverse events.

Read the detailed description

Colorectal ESD is an established organ-preserving technique for the en bloc resection of superficial colorectal neoplasia, particularly when conventional endoscopic mucosal resection is unlikely to achieve complete single-piece excision. However, colorectal ESD is technically demanding because of the thin colonic wall, unstable scope position, narrow submucosal space, intraprocedural bleeding, smoke generation, and difficulty in maintaining a stable dissection plane.

Underwater ESD has emerged as a modified operative environment in which luminal insufflation is discontinued and the target segment is immersed in saline. Saline immersion may improve visualization of the submucosal layer and of submucosal vessels, limit smoke persistence in the operative field, and facilitate more stable dissection. Although initial retrospective and comparative experiences have suggested procedural advantages of underwater ESD, high-quality randomized comparative data remain limited, particularly in Western multicenter practice.

This study was therefore designed as a prospective multicenter randomized trial across Italian tertiary referral centers to compare underwater ESD with conventional gas-assisted ESD for colorectal neoplasia referred for ESD. Patients were allocated 1:1 to either UESD or GESD. The primary endpoint was en bloc resection. Secondary endpoints included R0 resection, procedural time, dissection speed, intraprocedural bleeding, need for hemostatic forceps, smoke interference, vessel visualization, cutting-plane visualization, post-procedural pain, post-ESD coagulation syndrome, perforation, and delayed bleeding. The technical conduct of ESD apart from the assigned luminal environment was left to expert operator discretion in order to preserve real-world tertiary-center practice.

02

Conditions studied

  • Colorectal Neoplasia
  • Colorectal Superficial Neoplasia
  • Colorectal Precancerous Lesions

Keywords

  • colorectal ESD
  • underwater ESD
  • endoscopic submucosal dissection
  • colorectal neoplasia
  • en bloc resection
03

In context

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 388 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Adults aged 19 years or older

Colorectal neoplastic lesion referred for endoscopic submucosal dissection

Lesion considered amenable to en bloc endoscopic resection by ESD according to expert pre-procedural endoscopic assessment

Written informed consent provided

Exclusion criteria

Exclusion Criteria:

Known or suspected deep invasive neoplasia

Inflammatory bowel disease

Uninterrupted antithrombotic therapy

Known coagulopathy

Any clinical or lesion-related condition considered unsuitable for colorectal ESD by the treating endoscopist

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Underwater Endoscopic Submucosal Dissection (UESD)

    Underwater endoscopic submucosal dissection was performed after placement of the lesion on the anti-gravity side whenever feasible, discontinuation of luminal insufflation, and filling of the target colonic segment with saline solution to obtain stable immersion of the operative field. After immersion, mucosal incision and submucosal dissection were completed according to standard ESD principles, using either a conventional stepwise or tunnel-based strategy according to lesion characteristics and operator preference. Only saline solution was standardized across centers; device selection, generator settings, and ancillary maneuvers were otherwise left to operator discretion. Hemostasis, when required, was achieved using hemostatic forceps.

    Procedure: Underwater ESD (UESD)

  • Active comparator
    Conventional Gas-Assisted Endoscopic Submucosal Dissection (GESD)

    Conventional colorectal ESD was performed under gas insufflation according to standard practice at each participating center. Mucosal incision and submucosal dissection were carried out according to standard ESD technique. Device selection, generator settings, and technical dissection strategy were left to operator discretion. Hemostasis, when required, was achieved using hemostatic forceps.

    Procedure: Conventional Gas-Assisted ESD (GESD)

Interventions

  • ProcedureUnderwater ESD (UESD)

    Underwater ESD (UESD) performed under saline immersion with luminal insufflation turned off.

  • ProcedureConventional Gas-Assisted ESD (GESD)

    Conventional colorectal ESD was performed under gas insufflation according to standard practice at each participating center. Mucosal incision and submucosal dissection were carried out according to standard ESD technique. Device selection, generator settings, and technical dissection strategy were left to operator discretion. Hemostasis, when required, was achieved using hemostatic forceps.

06

What researchers measure

Primary outcomes

  1. En bloc resection rate

    Proportion of lesions resected in a single specimen.

    Time frame: During the index procedure

Secondary outcomes

  1. R0 resection rate

    Proportion of lesions resected en bloc with histologically negative lateral and vertical margins.

    Time frame: During index procedure and histopathological assessment within 30 days

  2. Procedural time

    Time from submucosal injection to completion of lesion dissection.

    Time frame: During the index procedure

  3. Dissection speed

    Rate of dissection calculated by dividing specimen area by dissection time.

    Time frame: During the index procedure

  4. Intraprocedural bleeding rate

    Proportion of procedures with any bleeding occurring during ESD.

    Time frame: During the index procedure

  5. Use of hemostatic forceps

    Proportion of procedures requiring coagulation forceps for active bleeding or prophylactic vessel coagulation.

    Time frame: During the index procedure

  6. Smoke interference

    Proportion of procedures in which electrocautery-generated fumes/particulate matter impaired visualization and required repeated lens irrigation or temporary withdrawal.

    Time frame: During the index procedure

  7. Vessel visualization score

    Operator-reported 5-point Likert score assessing clarity of identification of submucosal vessels during dissection. Lower scores indicate better visualization.

    Time frame: Immediately after the index procedure

  8. Cutting-plane visualization score

    Operator-reported 5-point Likert score assessing clarity of the dissection interface between submucosa and muscularis propria. Lower scores indicate better visualization.

    Time frame: Immediately after the index procedure

  9. Post-procedural abdominal pain

    Post-procedural pain assessed on a 0-3 numerical scale by nursing staff.

    Time frame: 15, 30, and 60 minutes after the procedure

  10. Post-ESD coagulation syndrome (PECS)

    Proportion of patients with abdominal distension or pain at the resection site associated with fever or inflammatory response in the absence of documented perforation.

    Time frame: Within 7 days

  11. Perforation rate

    Proportion of intraprocedural or delayed perforations.

    Time frame: From procedure to 30 days

  12. Delayed bleeding rate

    Proportion of patients with clinically overt post-procedural bleeding or hemoglobin decrease \>2 g/dL without another source.

    Time frame: From procedure to 30 days

07

Study locations

1 site
  • Campus Bio Medico Hospital
    Rome, RM 00100, Italy
08

References and documents

Individual participant data

Plan to share: Yes — Anonymsed data upon written and motivated requests

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07490574
Lead sponsor
University of Roma La Sapienza
Collaborators
Campus Bio-Medico University
Responsible party
Giulio Antonelli (MD, PhD, University of Roma La Sapienza) — Principal investigator
First posted
Mar 24, 2026
Start date
Dec 1, 2024
Primary completion
Dec 1, 2025
Completion
Mar 1, 2026
Last update
Mar 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion